Core Viewpoint - Fate Therapeutics reported a quarterly loss of $0.27 per share, which aligns with the Zacks Consensus Estimate and shows an improvement from a loss of $0.31 per share a year ago, indicating a positive trend in financial performance [1] Financial Performance - The company posted revenues of $1.37 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 8.73% and down from $1.86 million in the same quarter last year [2] - Over the last four quarters, Fate Therapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Fate Therapeutics shares have increased by approximately 50.6% since the beginning of the year, significantly outperforming the S&P 500, which gained 1.5% [3] Future Outlook - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.30 for the coming quarter and -$1.16 for the current fiscal year, alongside expected revenues of $1.5 million and $6 million respectively [7] - The Zacks Rank for Fate Therapeutics is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Fate Therapeutics belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable environment for stocks within this sector [8]

Papa John's (PZZA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.50%. A quarter ago, it was expected that this pizza chain would post earnings of $0.4 per share when it actually produced earnings of $0.32, delivering a surprise of -20%.Over the last four quarters, the company has ...

Vericel Corporation (VCEL) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.74%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.1, delivering a surprise of +600%.Over the last four quarters, the company has surpassed ...

ACM Research, Inc. (ACMR) came out with quarterly earnings of $0.25 per share, missing the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -35.90%. A quarter ago, it was expected that this company would post earnings of $0.47 per share when it actually produced earnings of $0.36, delivering a surprise of -23.4%.Over the last four quarters, the comp ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.04 per share, missing the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $1.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.99%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.88 per share when it actually produced earnings of $2.25, delivering a surprise of +19.68%.Over t ...

FTI Consulting (FCN) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +28.52%. A quarter ago, it was expected that this business advisory firm would post earnings of $1.93 per share when it actually produced earnings of $2.6, delivering a surprise of +34.72%.Over the last four quarters ...

Shift4 Payments (FOUR) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.24%. A quarter ago, it was expected that this company would post earnings of $1.46 per share when it actually produced earnings of $1.47, delivering a surprise of +0.68%.Over the last four quarters, the company h ...

Hertz Global Holdings, Inc. (HTZ) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $1.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -18.11%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.12, delivering a surprise of +700%.Over the last four quarters, the compa ...

Core Viewpoint - USA Compression Partners (USAC) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based on the Zacks Consensus Estimate, which aggregates EPS estimates from sell-side analysts for the current and following years [2]. - The Zacks rating upgrade reflects a favorable change in the earnings outlook for USA Compression, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors often adjust their valuations based on earnings estimates, leading to significant stock price movements as they buy or sell shares [5]. Recent Performance of USA Compression - For the fiscal year ending December 2026, USA Compression is projected to earn $1.32 per share, which remains unchanged from the previous year [9]. - Over the past three months, the Zacks Consensus Estimate for USA Compression has increased by 9%, indicating a positive trend in earnings estimates [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of USA Compression to a Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [11].

Investors might want to bet on JBT Marel (JBTM) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since ...